Alnylam Pharmaceuticals/$ALNY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
Ticker
$ALNY
Sector
Primary listing
Employees
2,500
Headquarters
Website
ALNY Metrics
BasicAdvanced
$39bn
73.93
$3.95
0.30
-
Price and volume
Market cap
$39bn
Beta
0.3
52-week high
$495.55
52-week low
$261.45
Average daily volume
1.1m
Financial strength
Current ratio
3.127
Quick ratio
2.885
Long term debt to equity
250.803
Total debt to equity
276.203
Interest coverage (TTM)
2.85%
Profitability
EBITDA (TTM)
806.943
Gross margin (TTM)
80.83%
Net profit margin (TTM)
12.55%
Operating margin (TTM)
17.54%
Effective tax rate (TTM)
1.68%
Revenue per employee (TTM)
$1,710,000
Management effectiveness
Return on assets (TTM)
10.06%
Return on equity (TTM)
90.36%
Valuation
Price to earnings (TTM)
73.93
Price to revenue (TTM)
8.979
Price to book
36.24
Price to tangible book (TTM)
36.24
Price to free cash flow (TTM)
59.832
Free cash flow yield (TTM)
1.67%
Free cash flow per share (TTM)
4.881
Growth
Revenue change (TTM)
82.57%
Earnings per share change (TTM)
-320.27%
3-year revenue growth (CAGR)
55.35%
10-year revenue growth (CAGR)
64.30%
3-year earnings per share growth (CAGR)
-23.10%
10-year earnings per share growth (CAGR)
-0.22%
What the Analysts think about ALNY
Analyst ratings (Buy, Hold, Sell) for Alnylam Pharmaceuticals stock.
ALNY Financial Performance
Revenues and expenses
ALNY Earnings Performance
Company profitability
ALNY News
AllArticlesVideos
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden
Business Wire·1 day ago
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM
Business Wire·1 week ago
New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Alnylam Pharmaceuticals stock?
Alnylam Pharmaceuticals (ALNY) has a market cap of $39B as of May 13, 2026.
What is the P/E ratio for Alnylam Pharmaceuticals stock?
The price to earnings (P/E) ratio for Alnylam Pharmaceuticals (ALNY) stock is 73.93 as of May 13, 2026.
Does Alnylam Pharmaceuticals stock pay dividends?
No, Alnylam Pharmaceuticals (ALNY) stock does not pay dividends to its shareholders as of May 13, 2026.
When is the next Alnylam Pharmaceuticals dividend payment date?
Alnylam Pharmaceuticals (ALNY) stock does not pay dividends to its shareholders.
What is the beta indicator for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals (ALNY) has a beta rating of 0.3. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.